22286 A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma Principal Investigator: Marc L. Friedman, M.D Status: Active Disease: Unresectable Hepatocellular (Liver) Cancer Summary: Therasphere® is microscopic glass beads embedded with Yttrium-90, a form of high-energy radiation used to treat cancers, in this case, liver cancer that cannot be surgically removed. It is also used as neoadjuvant therapy to shrink the liver tumor before liver surgery or transplant.
A Humanitarian Use Device (HUD) is intended to benefit patients by treating or diagnosing a disease or condition that affects fewer than 4,000 individuals in the United States per year. They are FDA approved to incentivize the development of devices for diseases affecting small populations because of high development costs. Treatment under the HDE Treatment Protocol is not investigational, not part of a clinical trial but does permit ongoing investigation of the clinical outcomes of the HUD according to institutional practices, monitored by the IRB.
An Imaging Nurse or Technologist will discuss participating with you, if you are interested. Once screened for eligibility, you will be provided any preparation instructions required for the study.
This website converts English to other languages using an automated tool called Microsoft Translator™. The translations may include errors or change the intended meaning of the text. Please consult your healthcare provider about any medical information.
Translations may not be available for some items, including PDF documents, maps, video captions, and text that appears on photos. Also, some features on the website may not work in the translated versions.